Related Experiment Video

Updated: May 22, 2025

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

6.8K

From metabolic regulation to kidney protection: β-arrestin 2 as a dual-function therapeutic target

Jian Yang1,2,3, Cheng-Zhi Zhang1,2,3,4, Jing Zhang1,2,5

  • 1Hubei Key Laboratory of Ischemic Cardiovascular Disease, Yichang 443000, Hubei Province, China.

World Journal of Diabetes
|March 17, 2025
PubMed

Insights

Beta-arrestin 2 knockout protects against diabetic nephropathy. Targeting beta-arrestin 2 offers a novel therapeutic strategy for kidney disease and metabolic disorders.

Area of Science:

  • Biomedical research
  • Molecular biology
  • Endocrinology

Background:

  • Recent studies highlight beta-arrestin 2's role in cellular signaling and disease.
  • Diabetic nephropathy is a major complication of diabetes with limited treatment options.
  • Metabolic regulation, including insulin signaling and glucose production, is complex and involves multiple pathways.

Purpose of the Study:

  • To investigate the protective effects of beta-arrestin 2 knockout in diabetic nephropathy.
  • To explore the role of beta-arrestin 2 in metabolic regulation.
  • To identify beta-arrestin 2 as a potential therapeutic target for diabetic nephropathy and metabolic dysfunction.

Main Methods:

  • Utilized beta-arrestin 2 knockout models.
  • Assessed kidney function and pathology in the context of diabetes.
  • Analyzed key metabolic parameters related to insulin signaling, glucose production, and adipose tissue.

Main Results:

  • Beta-arrestin 2 knockout demonstrated significant protection against diabetic nephropathy.
  • Beta-arrestin 2 was found to be critical in regulating insulin signaling, hepatic glucose production, and adipose tissue function.
  • Tissue-specific roles of beta-arrestin 2 in metabolism and kidney protection were identified.

Conclusions:

  • Beta-arrestin 2 is a key mediator in diabetic nephropathy and metabolic regulation.
  • Targeting beta-arrestin 2 presents a promising therapeutic avenue for diabetic nephropathy.
  • Tissue-specific modulation of beta-arrestin 2 may enable targeted treatments for metabolic disorders and kidney disease.
Keywords:
Diabetic nephropathyMetabolic regulationMulti-target therapiesTherapeutic strategiesTissue-specific signalingType 2 diabetesβ-arrestin 1β-arrestin 2

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.6K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

303

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
564
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
466
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
439